Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer

Nature Reviews Urology, Published online: 24 October 2022; doi:10.1038/s41585-022-00671-5Androgen deprivation therapy potentiates cardiovascular morbidity and mortality, which is the most common cause of non-cancer-related death in patients with prostate cancer. Whether the mode of testosterone suppression affects the risk of cardiovascular adverse events is unclear, especially as the 2021 PRONOUNCE trial — which aimed to compare the cardiovascular risks of gonadotropin-releasing hormone (GnRH) antagonists with GnRH agonists — was prematurely terminated.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research